UPDATE: Gilead Press Release Regarding Phase 3 Harvoni Study
February 26, 2015 at 15:15 PM EST
Gilead Sciences, Inc. (NASDAQ: GILD) today announced results from a Phase 3 study, ION-4, evaluating the once-daily single tablet ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.